title: Clorazepate affects cell surface regulation of delta and kappa opioid receptors, thereby altering buprenorphine-induced adaptation in the rat brain.
abstract: Concomitant abuse of buprenorphine (BPN) and benzodiazepines (BZD) may relate to a pharmacodynamic interaction between the two. The objective of the present work was to investigate the acute and chronic effects of clorazepate (CRZ) alone or in combination with BPN on selective kappa opiate tritiated ligand [3H]-U69 593 and delta opiate radioligand [3H]-deltorphine II binding in the rat brain. Bmax (maximal receptor density) and Kd (the dissociation constant) were directly determined at different brain regions of interest (ROI) selected for high densities of kappa and/or delta receptors in rats treated with BPN and/or CRZ. The agents were administered either once or for 21 consecutive days. Differences in Bmax and Kd (for both specific ligands) were related to drug treatment and receptor location. Globally, single BPN administration induced no changes in kappa or delta opiate receptor binding, whereas repeated BPN administration up-regulated kappa receptor density and decreased delta affinity. At the kappa receptor level, repeated administration of CRZ acted only on Kd, whereas the delta receptor was up-regulated. Repeated addition of CRZ to BPN had no effect on kappa receptor Bmax versus chronic controls. By significantly decreasing Bmax, CRZ nullified the effect of chronic BPN on the kappa receptor. The modifications were strongest in the nucleus accumbens, where both types of receptor occur. Treatments had region-selective effects in some brain areas, such as the amygdala, periaqueductal gray matter, hypothalamus and caudate putamen. Increased mu and delta receptor densities would be expected to provide reinforcement by enhancing reward, and impairment of kappa receptor availability would be expected to decrease aversion. The effects described are likely to influence addictive behavior among people abusing BZD and BPN.
authors.affiliation: UMR CEA E2-FRE CNRS 2698 Research Group, Center Cyceron, 15 Boulevard Henry Becquerel, 14070 Caen cedex, France. quentin@cyceron.fr
authors.forename: Thomas
authors.initials: T
authors.lastname: Quentin
authors.forename: Daniele
authors.initials: D
authors.lastname: Debruyne
authors.forename: Veronique
authors.initials: V
authors.lastname: Lelong-Boulouard
authors.forename: Geraldine
authors.initials: G
authors.lastname: Poisnel
authors.forename: Louisa
authors.initials: L
authors.lastname: Barre
authors.forename: Antoine
authors.initials: A
authors.lastname: Coquerel
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001921:Brain / Q000166:cytology / Q000187:drug effects; D002047:Buprenorphine / Q000494:pharmacology*; D003009:Clorazepate Dipotassium / Q000494:pharmacology*; D004347:Drug Interactions; D008297:Male; D009292:Narcotic Antagonists / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017465:Receptors, Opioid, delta / Q000187:drug effects / Q000378:metabolism*; D017473:Receptors, Opioid, kappa / Q000187:drug effects / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D014151:Anti-Anxiety Agents; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D002047:Buprenorphine; D003009:Clorazepate Dipotassium